TTX-030 in Combination With Immunotherapy and/or Chemotherapy in Subjects With Advanced Cancers

PHASE1CompletedINTERVENTIONAL
Enrollment

185

Participants

Timeline

Start Date

March 30, 2020

Primary Completion Date

November 30, 2022

Study Completion Date

March 27, 2024

Conditions
Solid Tumor, Adult
Interventions
COMBINATION_PRODUCT

TTX-030, budigalimab and mFOLFOX6

Dose and schedule per protocol

COMBINATION_PRODUCT

TTX-030, budigalimab and docetaxel

Dose and schedule per protocol

COMBINATION_PRODUCT

TTX-030 and mFOLFOX6

Dose and schedule per protocol

COMBINATION_PRODUCT

TTX-030 and budigalimab

Dose and schedule per protocol

COMBINATION_PRODUCT

TTX-030, budigalimab, nab-paclitaxel and gemcitabine

Dose and schedule per protocol

COMBINATION_PRODUCT

TTX-030 and pembrolizumab

Dose and schedule per protocol

COMBINATION_PRODUCT

TTX-030, nab-paclitaxel and gemcitabine

Dose and schedule per protocol

COMBINATION_PRODUCT

Budigalimab and mFOLFOX6

Dose and schedule per protocol

Trial Locations (32)

10408

National Cancer Center, Ilsandong-gu

10461

Montefiore Medical Center, The Bronx

13620

Seoul National University, Seongnam-si Bundan-gu

15232

UPMC Hillman Cancer Center, Pittsburgh

22031

Virginia Cancer Specialists, Fairfax

29605

Prisma-Health Cancer Institute, Greenville

31904

IACT Health - John B. Amos Cancer Center, Columbus

32835

Orlando Health UF Health Cancer Center, Orlando

33136

Sylvester Comprehensive Cancer Center, University of Miami Miller School of Medicine, Miami

34474

Ocala Oncology Center PL, Ocala

37203

Sarah Cannon Research Institute, Nashville

38138

West Cancer Center and Research Institute, Germantown

40202

Norton Cancer Institute, Louisville

43614

University of Toledo, Toledo

44122

University Hospitals Cleveland Medical Center, Cleveland

49201

National Cancer Center, Seogu

53226

Froedtert Hospital & Medical College of Wisconsin, Milwaukee

60637

University of Chicago Medical Center, Chicago

68130

Nebraska Cancer Center Oncology Hematology West P.C., Omaha

70121

Ochsner Medical Center, New Orleans

78229

NEXT Oncology, San Antonio

84112

Hunstman Cancer Intitute, Salt Lake City

85258

HonorHealth Research Institute, Scottsdale

90007

University of Southern California, Los Angeles

90048

Cedars-Sinai Medical Center, Los Angeles

90404

UCLA Hematology/Oncology, Los Angeles

91010

City of Hope Medical Center Clinical Trials Office, Duarte

92868

Chao Family Comprehensive CC, UCI, Orange

95817

UC Davis Comprehensive Cancer Center, Sacramento

06351

Samsung Medical Center, Gangnam-gu

03722

Severance Hospital Yonsei University, Seodaemun-gu

05505

Asan Medical Center, Songpa-gu

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

AbbVie

INDUSTRY

lead

Trishula Therapeutics, Inc.

INDUSTRY